Evidence map›Paper›PMID 41530145›Full record

ArticleNature communications2026

CD39 polymorphism enables lung thrombosis in sickle cell disease.

Tomasz Brzoska, Tomasz W Kaminski, Omika Katoch, Elizaveta V Menchikova, Adekunle E Alagbe, Sarah E Tashbook, Stevan P Tofovic, Jude C Jonassaint, Claudette M St Croix, Simon C Watkins and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Tomasz BrzoskaPittsburgh Heart, Lung and Blood Vascular Medicine Institute, Pittsburgh, PA, USA. brzoskat@pitt.edu.ORCID http://orcid.org/0000-0002-7431-3590
Tomasz W KaminskiPittsburgh Heart, Lung and Blood Vascular Medicine Institute, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0002-8688-4171
Omika KatochPittsburgh Heart, Lung and Blood Vascular Medicine Institute, Pittsburgh, PA, USA.
Elizaveta V MenchikovaDepartment of Pharmacology & Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA.
Adekunle E AlagbePittsburgh Heart, Lung and Blood Vascular Medicine Institute, Pittsburgh, PA, USA.
Sarah E TashbookPittsburgh Heart, Lung and Blood Vascular Medicine Institute, Pittsburgh, PA, USA.
Stevan P TofovicDivision of Pulmonary Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Jude C JonassaintDivision of Classical Hematology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Claudette M St CroixCenter for Biologic Imaging, University of Pittsburgh, Pittsburgh, PA, USA.
Simon C WatkinsCenter for Biologic Imaging, University of Pittsburgh, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0003-4092-1552
Shane HoweTranslational Hematology Program, Versiti Blood Research Institute and Blood Center of Wisconsin, Milwaukee, WI, USA.
Joshua J FieldTranslational Hematology Program, Versiti Blood Research Institute and Blood Center of Wisconsin, Milwaukee, WI, USA.
Amanda A SeyerleUniversity of North Carolina, Chapel Hill, NC, USA.
Tirthadipa Pradhan-SunddTransfusion Medicine, Vascular Biology and Cell Therapy Program, Versiti Blood Research Institute and Blood Center of Wisconsin, Milwaukee, WI, USA.
Cecilia LaurieDepartment of Epidemiology, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-6569-2501
Nathan D PankratzDepartment of Laboratory Medicine & Pathology, University of Minnesota, Minneapolis, MN, USA.ORCID http://orcid.org/0000-0001-5958-693X
Nicholas L SmithDepartment of Epidemiology, University of Washington, Seattle, WA, USA.
Ellen L GoodeMayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-9094-8326
James S PankowDivision of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN, USA.ORCID http://orcid.org/0000-0001-7076-483X
Charles KooperbergFred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-7986-8560
Gregory J KatoBlood Science Consulting, Tilghman, MD, USA.
Yingze ZhangDivision of Pulmonary Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0001-6947-2901
Enrico M NovelliPittsburgh Heart, Lung and Blood Vascular Medicine Institute, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0003-3010-8285
Mark T GladwinUniversity of Maryland School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-7267-9006
Edwin K JacksonDepartment of Pharmacology & Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0002-8101-6009
Seyed M NouraieDivision of Pulmonary Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0001-7465-0581
Prithu SunddPittsburgh Heart, Lung and Blood Vascular Medicine Institute, Pittsburgh, PA, USA. psundd@versiti.org.ORCID http://orcid.org/0000-0001-7568-5719

Funding

Pulmonary arteriole occlusion by platelet-neutrophil micro-emboli in Acute Chest SyndromeR01HL128297 · NHLBI · VERSITI WISCONSIN, INC. · PI SUNDD, PRITHU · 2015 to 2025
$5.4M
Mechanisms of platelet exosome-mediated acute chest syndrome in sickle cell diseaseR01HL141080 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI NEAL, MATTHEW D, NOVELLI, ENRICO M · 2019 to 2022
$3.1M
CD39-carrying extracellular vesicles regulate pulmonary thrombosis in Sickle Cell DiseaseR01HL166345 · NHLBI · VERSITI WISCONSIN, INC. · PI Prithu Sundd · 2023 to 2026
$3.1M
American Heart Association (American Heart Association, Inc.) 18TPA34170588American Heart Association (American Heart Association, Inc.) 23TPA1074022NHLBI NIH HHS R01 HL128297NHLBI NIH HHS R01 HL166345U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL128297U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL141080U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL166345
6 · The paper itself

Abstract

Sickle cell disease (SCD) is the most common monogenic-hemolytic disorder affecting people of African ancestry. Adenosine diphosphate (ADP) released following intravascular hemolysis activates platelets by stimulating purinergic receptors to promote thrombosis. Despite brisk intravascular hemolysis, which releases high levels of ADP into plasma, and evidence of platelet and hemostatic activation, it remains elusive why only a subset of SCD patients develop lung thrombosis. Using real-time in vivo lung microscopy, we report a surprising finding that humanized SCD mice are protected from ADP-induced lung thrombosis, which is secondary to the degradation of ADP by CD39 present in circulating extracellular vesicles released by the lung endothelium. ADP-induced platelet aggregation is also impaired in the blood of SCD patients with elevated levels of CD39

Indexed as

Anemia, Sickle CellAntigens, CDApyraseLung DiseasesThrombosisAdenosine DiphosphateAnimalsBlood PlateletsFemaleHumansLungMaleMicePlatelet AggregationPolymorphism, Single NucleotideAdenosine DiphosphateAntigens, CDApyraseCD39 antigen

Identifiers

PMID41530145
PMCPMC12909804

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.